is learned is so immediately applicable to the care of the sick child. Recent advances have added to rather than diminished the importance of the nursing care, the standards of which are often decisive in the battle between life and death in the ill newborn baby.
Mr Eoin Aberdeen (Hospital for Sick Children, Great Ormond Street, London) read a paper entitled Neonatal Cardiac Surgery. REFERENCE Aberdeen E & Wooler G H eds (1967) Cancer of the breast is now the commonest cancer in women. In England and Wales it accounts annually for 10,000 deaths. Recent advances in treatmentby surgery, radiotherapy, alteration of the endocrine environment and clhemotherapy have apparently done little to improve the prognosis and neither in Great Britain (Adams & Spicer 1965) nor the United States (Cutler 1966) has the mortality of the disease altered in the past thirty years (Figs 1, 2) . This contrasts with the improvement in the prognosis of cancer of the colon during the same period (Fig 2) , of which five-year survival rates in the United States have increased from 26% in 1940-4 to 46% of cases diagnosed in 1955-9. Comparable statistics for cancer of the breast are 51 % and 57% (Cutler 1966 -1940 - -44 1945 - -49 1950 - -54 1955 Five-year survival rates (°) ofpatients with cancer of the breast and colon first diagnosed between 1940 and 1959 in the USA (from data ofCutler 1966) Improvement in these statistics can result only from revision of our whole therapeutic approach. Continued haggling about the relative value of the various methods used to control the disease locally does no good, for none of the methods currently used can be regarded as satisfactory.
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Primary Treatment
Although adequate local treatment at the time cancer of the breast is first diagnosed may prolong survival (Bloom 1962) , it is becoming increasingly apparent that its type and extent has little influence on the prognosis of the disease. This can be exemplified by the following four points:
(1) A wide variety of operations ranging from simple removal of the lump to super-radical surgery are practised by the leaders of breast surgery in different countries (Table 1) . It is difficult to believe that each surgeon is other than Table I Operations currently used to treat primary breast cancer Removal of lump (Porritt 1964) Simple mastectomy (McWhirter 1955 , Crile 1965 Radical mastectomy: Classical (Halsted 1894 , Haagensen et al. 1963 Modified (Patey & Dyson 1948 , Handley 1964 Extended (Urban & Baker 1952 , Urban 1964 Super-radical (Wangensteen 1950 , Andreasson et al. 1954 convinced that the method of treatment he adopts is as goodif not betterthan that practised by his colleagues.
(2) The results of an international co-operative study, in which all patients were treated within a single system of clinical classification (Columbia A+B), shows little difference in the survival rates following a variety of therapeutic policies (Haagensen et al. 1963) (Fig 3) . Although the results of Haagensen's own patients (New York, Fig 3) are apparently better than those in the other groups and have been regarded as demonstrating that radical mastectomy is superior to other methods of treatment (Lancet 1963) , it should be noted that they are not in accord with those from St Louis and that excluded, in part, from his series, are patients in whom a positive biopsy of an upper axillary node was deemed to indicate inoperability.
(3) There is no difference between the survival rates of primary cancer of the breast diagnosed in south-east Scotland and in centres in England and Wales in which the policy of primary treatment is widely different (Table 2) . Table 2 Comparison of overall five-year crude survival rates for patients with breast cancer in south-east Scotland and in other regions in England & Wales (Forrest 1962 (4) The published results of several prospective controlled trials have shown identical survival rates when different methods of treatment are allocated randomly to patients with primary disease (Table 3) .
Survival rates apart, adequate local treatment improves symptoms and relieves the patient from anxiety and discomfort. However, need this imply mutilation? Even if we do believe that removal of the upper axillary nodes is indicated, the work of (1948), Kendall et al. (1963) , and Handley (1960 Handley ( , 1964 has shown that this can equally well be performed without sacrifice of the main adductor mass of the forearm. Biology and immune status: It is well established that the histological grade of a primary tumour of the breast, based on the degree of tubule formation, the regularity of nuclear size and the shape and staining properties of the nuclei, bears a profound relationship to survival (Bloom 1962) ( Fig 4) . Less well recognized is the finding that tumours with a smooth, well-delimited contour have a better prognosis than those which have an irregular spiculated outline (Lane et al. 1961 ) ( Fig 5) . In Lane's series the ten-year survival rate of 46 patients with tumours of smooth outline was 80% compared with 38% in 158 patients with tumours which were spiculated. Tumours with smooth contours show marked lymphocytic infiltration and this factor too is associated with prognosis (Black 1965) . Thus, Berg (1962) found that the survival ofpatients with anaplastic duct carcinomas of the breast was considerably influenced by the degree of lymphocytic infiltration of the tumour (Fig 6) . This may in turn be associated with sinus histiocytosis in the regional lymph nodes, a factor which also is related to prognosis (Black 1965) .
These three associationssmooth contour, lymphocytic infiltration and sinus histiocytosis in regional nodesall of which apparently affect prognosis in the same directionmay be one aspect of the normal immunological response to a tumour. This supports the possibility that stimulation of the immune response, e.g. by a bacterial antigen, may be a worth-while form of adjuvant therapy in certain types of breast cancer (Woodruff & Boak 1965 ).
Endocrine status: No less complex are the relationships which exist between the endocrine status and the behaviour of a cancer of the breast. Some are apparently paradoxicalfor instance, the effect of the menopause, which on the one hand influences unfavourably the course of a tumour arising concurrently with it and yet, on the other, possibly influences beneficially (by prolonging the 'free interval') tumours whose onset occurs in premenopausal life (Smithers & Payne 1962) . Pregnancy may well have an equally paradoxical effect, influencing unfavourably tumours which appear during its later months yet possibly protecting patients when it occurs subsequent to the primary treatment of a breast tumour (Fig 7) (White 1955, Bloom 1962 , Peters & Meakin 1965 .
In the light of this information there is little justification for advising a young woman with breast cancer to avoid pregnancy and thus incur additional psychological worries.
Recently, Bulbrook et al. (1964) have found that an abnormality of steroid secretion, characterized by abnormally low levels of Eetiocholanolone (a metabolite of dehydroepiandrosterone, an adrenal androgen) in the urine, when detected at the time of primary treatment of a breast cancer, may be associated with a poor prognosis. This work provides further evidence that the prognosis of breast cancer is already determined at the time of primary treatment and raises the possibility that additive therapy with androgens to correct the abnormality and restore normal hormonal balance may influence the disease beneficially. This possibility is currently under trial (Hayward 1964) .
The value of alteration of the endocrine status by 'prophylactic' castration is controversial. Although Cole (1964) has found, in a randomized controlled study in premenopausal women, that suppression of ovarian function at the time of mastectomy prolongs recurrence-free survival, it is now becoming doubtful if the benefit is greater than that which follows timely 'therapeutic' castration when indicated by recurrent or metastatic disease.
Extent ofSpread
To the practising surgeon the most important factor in determining prognosis is the extent of the disease at the time of primary treatment. One index of this is the size of the tumour and, in general, the larger the tumour the worse the prognosis (Fig 8) . Another is the state of the axillary nodes (Fig 9) in the axillary nodes, have found the latter to be dominant (Fig 10) . Clinical staging by the TNM system, which takes both size of tumour and the clinical state of the axillary nodes into account, has therefore proved a useful prognostic guide (Harmer 1966) .
The greater the number of axillary nodes the worse is the prognosis (Pickren 1961) and as a result of a detailed examination of 204 radical mastectomy specimens Auchingloss (1963) has concluded that involvement of nodes above the lower border of pectoralis minor indicates incurability. If this is so -and there seems little reason to doubt it -there is little justification for supporting extensive axillary dissection with its inherent morbidity as part of primary treatment and every justification for adopting, as a standard operation for primary breast cancer, removal of the breast and the lower axillary nodes alone.
In Cardiff Dr P B Kunkler, director of radiotherapy, and Iwill shortlyembark on a preliminary trial in which this operation will form the basis of our routine treatment for primary cancer of the breast. The biological characteristics of the tumour and the endocrine status of the patient will be fully documented and related to the extent of the disease at the time of treatment and to its future behaviour. The extent of the disease as defined by TNM staging, skeletal X-rays, mammography of both breasts, and biopsy of supraclavicular and internal mammary lymph nodes, will determine the need for subsequent therapy.
We believe that, until a new approach to the treatment of breast cancer is developed, rational therapy depends on an accurate assessment of the spread of the disease and giving such treatment as may be required to control its local manifestations with minimal morbidity. Until such time as it is proved that adjuvant systemic treatment, by endocrine manoeuvres andchemotherapy, prolongs useful and comfortable lifeand the controlled trials being carried out in the United States, Britain and Norway will soon answer this question (Noer 1963 , Cole 1964 , Nissen-Meyer 1966 we would prefer to keep it until required for the control of recurrent or metastatic disease.
